Metsera, Inc. (MTSR)
Automate Your Wheel Strategy on MTSR
With Tiblio's Option Bot, you can configure your own wheel strategy including MTSR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MTSR
- Rev/Share 0.0
- Book/Share 4.2833
- PB 16.5457
- Debt/Equity 0.0024
- CurrentRatio 5.2594
- ROIC -0.5903
- MktCap 7444841694.0
- FreeCF/Share -1.6989
- PFCF -41.7832
- PE -24.1466
- Debt/Assets 0.0017
- DivYield 0
- ROE -0.8976
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | MTSR | Wells Fargo | Overweight | Equal Weight | -- | $54 | Sept. 30, 2025 |
| Initiation | MTSR | Leerink Partners | -- | Outperform | -- | $77 | Sept. 9, 2025 |
| Initiation | MTSR | Wells Fargo | -- | Overweight | -- | $65 | June 20, 2025 |
| Initiation | MTSR | BofA Securities | -- | Buy | -- | $38 | Feb. 25, 2025 |
| Initiation | MTSR | Evercore ISI | -- | Outperform | -- | -- | Feb. 25, 2025 |
| Initiation | MTSR | Guggenheim | -- | Buy | -- | $56 | Feb. 25, 2025 |
News
Pfizer to acquire Metsera after winning bidding contest against Novo Nordisk
Published: November 10, 2025 by: Proactive Investors
Sentiment: Positive
Metsera (NASDAQ:MTSR) announced that it has entered into an amended merger agreement with Pfizer Inc (NYSE:PFE, ETR:PFE), under which Pfizer will acquire the biotech company for up to $86.25 per share, valuing it at about $10 billion. The offer consists of $65.60 per share in cash and a contingent value right (CVR) for additional payments of up to $20.65 per share based on clinical and regulatory milestones.
Read More
Pfizer to buy Metsera in deal worth up to $10 billion
Published: November 10, 2025 by: CNBC Television
Sentiment: Positive
Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk. Metsera accepted a sweetened offer from Pfizer late on Friday, citing U.S. antitrust risks in Novo's bid that it had previously called superior.
Read More
Pfizer CEO: Metsera deal gives us 'one of the most exciting, advanced portfolios' in obesity drugs
Published: November 10, 2025 by: CNBC Television
Sentiment: Positive
Pfizer CEO Albert Bourla joins Squawk on the Street to discuss the company's up to $10 billion acquisition of Metsera, the competitive landscape in obesity drugs, and Pfizer's strategy for clinical development and manufacturing.
Read More
5 Things to Know Before the Stock Market Opens
Published: November 10, 2025 by: Investopedia
Sentiment: Negative
Stock futures are surging this morning after U.S. lawmakers passed a key procedural hurdle as part of an agreement that could bring an end to the shutdown that has lasted nearly six weeks; President Donald Trump has proposed issuing $2,000 “dividend” checks to Americans that would be funded by revenue from tariffs; AI data center firm CoreWeave (CRWV) is set to release its quarterly results after the closing bell today; and shares of Metsera (MTSR) are plunging after the weight-loss drug maker announced that it would be acquired by Pfizer (PFE) after a bidding war with Novo Nordisk (NVO). Here's …
Read More
Novo CEO says its bid for Metsera is higher
Published: November 06, 2025 by: Reuters
Sentiment: Positive
Novo Nordisk CEO Mike Doustdar said during a White House event on Thursday that the company's bid for obesity biotech Metsera is higher than the one from rival Pfizer Inc. , which has sued both Metsera and Novo over the terms of their rival deal.
Read More
What is Metsera, the target in Pfizer's and Novo Nordisk's bidding war?
Published: November 06, 2025 by: Reuters
Sentiment: Positive
Pfizer and Novo Nordisk are locked in a bidding war for biotech firm Metsera as the pharmaceutical giants seek to augment their pipeline in the booming weight-loss drug market.
Read More
Pfizer To Raise Metsera Bid After Court Denies Attempt To Block Rival Deal
Published: November 06, 2025 by: Benzinga
Sentiment: Neutral
The Delaware Chancery Court denied Pfizer Inc.'s (NYSE:PFE) request for a temporary restraining order to prevent Metsera, Inc. (NASDAQ:MTSR) from terminating the existing merger agreement in favor of a competing proposal from Novo Nordisk A/S (NYSE:NVO).
Read More
Pfizer says it removed some conditions from its Metsera bid
Published: November 05, 2025 by: Reuters
Sentiment: Neutral
Pfizer has removed some conditions in its bid for Metsera as it tries to overcome a rival $10 billion bid by Novo Nordisk for the obesity drug developer, the U.S. drug giant said in a letter to a Delaware judge on Wednesday.
Read More
Healthy Returns: What to know about Pfizer and Novo Nordisk's bidding war over obesity biotech Metsera
Published: November 05, 2025 by: CNBC
Sentiment: Positive
Pfizer and Novo Nordisk are in a takeover clash over the obesity biotech Metsera, while some House Republicans warm to extending tax credits.
Read More
Novo Nordisk CEO Mike Doustdar on $10B Metsera bid, expanding use of obesity drugs
Published: November 05, 2025 by: CNBC Television
Sentiment: Positive
Novo Nordisk CEO Mike Doustdar joins 'Squawk Box' to discuss the company's quarterly earnings results, the company's bid for obesity biotech company Metsera, negotiations with the Trump administration to sell some of its obesity drugs to consumers at a lower rate, expanding the use of obesity drug, and more.
Read More
Novo Nordisk tops Pfizer in bidding war for obesity startup Metsera
Published: November 04, 2025 by: Proactive Investors
Sentiment: Positive
Novo Nordisk (NYSE:NVO) has outbid Pfizer Inc (NYSE:PFE, ETR:PFE) in a heated contest for obesity-focused biotech Metsera (NASDAQ:MTSR), with the Danish drugmaker's revised offer valuing the company at roughly $10 billion, compared with Pfizer's $8.1 billion proposal. Metsera's board on Tuesday declared Novo Nordisk's amended bid “superior,” setting the stage for a potential acquisition that could reshape the obesity treatment landscape.
Read More
Pfizer and Novo Nordisk both raise bids for Metsera
Published: November 04, 2025 by: CNBC Television
Sentiment: Positive
CNBC's David Faber breaks down the latest details about a bidding war between Pfizer and Novo Nordisk for Metsera.
Read More
Delaware judge does not see current need for court in Metsera bidding war between Pfizer and Novo
Published: November 04, 2025 by: Reuters
Sentiment: Neutral
A Delaware judge said on Tuesday she did not see in a preliminary evaluation the need to involve the court in the bidding war for Metsera between Pfizer and Novo Nordisk, but did schedule another hearing for 3:15 pm ET on Wednesday to review the process.
Read More
Metsera said it received a revised acquisition offer from Novo Nordisk that it called superior to Pfizer's bid
Published: November 04, 2025 by: WSJ
Sentiment: Positive
The new offer constitutes a superior company proposal to Pfizer's bid, Metsera said.
Read More
Novo Nordisk submits updated proposal to acquire Metsera, Inc.
Published: November 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
Today, Novo Nordisk confirms that it has submitted an updated, unsolicited proposal to acquire Metsera. The updated proposal has been declared superior
Read More
Novo Nordisk, Pfizer sweeten bid for Metsera as bidding war heats up
Published: November 04, 2025 by: Reuters
Sentiment: Positive
Novo Nordisk and Pfizer have revised their bids for Metsera , the obesity drug developer said on Tuesday.
Read More
Novo Nordisk says Metsera bid won't raise antitrust issues
Published: November 03, 2025 by: Reuters
Sentiment: Positive
Denmark's Novo Nordisk said on Monday it is confident that its proposed takeover of U.S. drugmaker Metsera does not raise any antitrust issues.
Read More
Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech
Published: November 03, 2025 by: CNBC
Sentiment: Negative
Pfizer said it filed a second lawsuit against Novo Nordisk and Metsera, alleging that the Danish drugmaker's attempt to outbid Pfizer to acquire the obesity biotech is anticompetitive. The new suit escalates a heated standoff between Pfizer and Novo Nordisk over Metsera, whose obesity pipeline could yield new competitors in the blockbuster weight loss drug market.
Read More
Metsera Issues Statement in Response to Litigation
Published: November 03, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Nov. 3, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ: MTSR) ("Metsera" or the "Company") today issued the following statement in response to litigation filed against the Company by Pfizer: "Pfizer is trying to litigate its way to buying Metsera for a lower price than Novo Nordisk. Metsera's Board of Directors will continue to stand firm on behalf of shareholders and patients.
Read More
Pfizer Files Antitrust Suit to Block Novo Nordisk Acquisition of Metsera
Published: November 03, 2025 by: WSJ
Sentiment: Negative
Lawsuit says the proposed merger of the weight-loss drugmakers could kill off a smaller competitor.
Read More
Metsera the US obesity biotech at centre of Novo, Pfizer bidding war
Published: October 30, 2025 by: Reuters
Sentiment: Positive
Metsera has become the obesity drug market's hottest ticket.
Read More
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'
Published: October 30, 2025 by: Benzinga
Sentiment: Negative
On Thursday, Metsera Inc. (NASDAQ:MTSR) received an unsolicited acquisition proposal from Novo Nordisk A/S (NYSE:NVO).
Read More
Healthy Returns: Pfizer's new obesity bet, Metsera, releases encouraging data on lead drug
Published: September 30, 2025 by: CNBC
Sentiment: Positive
Metsera released data from mid-stage trials on its lead obesity drug candidate, while a high stakes Medicare open enrollment approaches.
Read More
Metsera Posts Promising Weight-Loss Drug Results. It Could Be a Win for Pfizer.
Published: September 30, 2025 by: Barrons
Sentiment: Positive
Pfizer said last week it would pay $47.50 per share for Metsera, and an extra $22.50 per share if its drugs hit certain milestones.
Read More
Pfizer's Metsera buy raises competitive heat for Novo Nordisk
Published: September 23, 2025 by: Proactive Investors
Sentiment: Negative
UBS has warned that Pfizer Inc's (NYSE:PFE, ETR:PFE) $7.3 billion acquisition of Metsera will sharpen competition for Novo Nordisk (NYSE:NVO) in the fast-growing obesity drug market, particularly towards the end of the decade. The bank kept its 'neutral' rating on Novo shares with a DKr340 price target, implying 12.5% downside from the current level.
Read More
Pfizer bets $7.3 billion on obesity drugs with Metsera buy
Published: September 22, 2025 by: Fast Company
Sentiment: Positive
Pfizer is fattening its drug portfolio by betting that more people will want to slim down. The New York drugmaker announced Monday that it's acquiring Metsera, and its portfolio of four medications for obesity and cardiometabolic diseases, in a deal valued at as much as $7.3 billion.
Read More
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ODP and MTSR on Behalf of Shareholders
Published: September 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 22, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: ODP Corporation (NASDAQ: ODP)'s sale to an affiliate of Atlas Holdings for $28.00 per share in cash.
Read More
Pfizer Stock Higher on Multi-Billion Dollar Metsera Buyout
Published: September 22, 2025 by: Schaeffers Research
Sentiment: Positive
Pfizer Inc (NYSE:PFE) stock is up 2.6% to trade at $24.65 at last check, after the pharma giant revealed it will buy weight-loss drug company Metsera (MTSR) in a deal valued up to $7.3 billion.
Read More
Shareholder Alert: The Ademi Firm investigates whether Metsera Inc. is obtaining a Fair Price for its Public Shareholders
Published: September 22, 2025 by: PRNewsWire
Sentiment: Neutral
MILWAUKEE , Sept. 22, 2025 /PRNewswire/ -- The Ademi Firm is investigating Metsera (Nasdaq: MTSR) for possible breaches of fiduciary duty and other violations of law in its transaction with Pfizer.
Read More
Pfizer acquires Metsera in $7.3B deal to boost obesity drug pipeline
Published: September 22, 2025 by: Proactive Investors
Sentiment: Positive
Pfizer Inc (NYSE:PFE, ETR:PFE) on Monday announced that it will acquire Metsera, Inc (NASDAQ: MTSR), a weight-loss drug developer, in a deal valued at up to $7.3 billion, or $47.50 per share in cash. Metsera is also eligible to receive an additional $22.50 per share contingent on the achievement of certain performance milestones.
Read More
About Metsera, Inc. (MTSR)
- IPO Date 2025-01-31
- Website https://metsera.com
- Industry Biotechnology
- CEO Christopher Whitten Bernard
- Employees 93